医療装置ならびに医療産業

市場、技術レポート


●Life Science Intelligence

U.S. Markets for Breast Disease Diagnostic And Therapeutic Technologies, 2007-2012
「米国の乳房疾患診断及び治療技術、2007-2012年」
価格: $3,950(時価換算円価格となります。消費税別)


U.S. Markets for Breast Disease Diagnostic
and Therapeutic Technologies, 2007

240 Pages
98 Exhibits
2007 Analysis
Forecasts through 2012


The U.S. breast disease diagnosis and therapy markets are poised for substantial and sustainable growth, according to this new report from Life Science Intelligence (LSI). The report, U.S. Markets for Breast Disease Diagnostic and Therapeutic Technologies, 2007, finds that the $550 million U.S. digital mammography segment is expected to grow more than 50% annually during the next 3 years as digital technology replaces analog. In addition, the $167 million US vacuum-assisted biopsy segment will also experience dramatic growth reaching over $350 million in the U.S. by 2012.

This in-depth report provides a deep and discrete analysis of the patients, procedures, technologies and companies driving growth and innovation in the U.S. markets for breast disease diagnosis and therapy. Coverage includes:

Non-Interventional Breast Disease Diagnosis -- Mammography, computer-aided diagnosis, magnetic resonance imaging, diagnostic ultrasound, screening ultrasound, and various other diagnostic methods.

Interventional Breast Disease Diagnosis -- Ultrasound-guided breast biopsy, stereotactic-guided breast biopsy, spring-loaded and vacuum-assisted biopsy techniques, and other methods.

Breast Disease Therapy – Treatment of benign breast disease including surgical intervention, cryoablation, thermoablation, and percutaneous excision. Treatment of malignant breast disease including surgical excision and breast brachytherapy.


1. EXECUTIVE SUMMARY

1.1 Methodology
1.2 Disease Incidence
1.3 Non‐Interventional Diagnosis
1.3.1 Screening and Diagnostic Mammography
1.3.2 Screening and Diagnostic Ultrasound
1.3.3 Magnetic Resonance Imaging
1.3.4 Other Non‐Interventional Modalities
1.4 Interventional Diagnosis
1.5 Breast Therapies and Therapeutic Devices

Exhibit 1.1: Incidence of Breast Cancer (2006-2012E)
Exhibit 1.3: Incidence of Benign Fibroadenomas (2006-2012E)
Exhibit 1.4: Non‐Interventional Breast Diagnostic System and Service Sales, Market Forecast (2006-2012E)
Exhibit 1.5: Screening Mammograms, Procedure Forecast (2006-2012E)
Exhibit 1.6: Full‐Field Digital Mammography System Sales, Market Forecast (2006-2012E)
Exhibit 1.7: Full‐Field Digital Mammography System Sales, Share by Supplier (2006)
Exhibit 1.8: Breast Ultrasound Market Forecast (2006-2012E)
Exhibit 1.9: Breast Ultrasound Market, Share by Supplier (2006)
Exhibit 1.10: Breast MRI Market Forecast (2006-2012E)
Exhibit 1.11: Breast MRI Market, Share by Supplier (2006)
Exhibit 1.12: Interventional Breast Diagnostic Disposable and Capital Equipment Sales, Market Forecast (2006-2012E)
Exhibit 1.13: Breast Biopsy Procedure Forecast, by Guidance Method (2006-2012E)
Exhibit 1.14: Breast Biopsy Devices Market Forecast (2006-2012E)
Exhibit 1.15: Spring‐Loaded Biopsy Device Sales, Share by Supplier (2006)
Exhibit 1.16: Vacuum‐Assisted Biopsy Device Sales, Share by Supplier (2006)
Exhibit 1.17: Biopsy Marker Device Market Forecast (2006-2012E)
Exhibit 1.18: Biopsy Marker Device Market, Share by Supplier (2006)
Exhibit 1.19: Excision Procedure Volume Forecast (2006-2012E)
Exhibit 1.20: Lumpectomy Procedure Volume Forecast (2006-2012E)
Exhibit 1.21: Breast Brachytherapy Market Forecast (2006-2012E)
Exhibit 1.22: Total Breast Healthcare Market Forecast, by Service Type (2006-2012E)
Exhibit 1.23: Total Breast Healthcare Market, by Service Type, (2006)
Exhibit 1.24: Total Breast Healthcare Market, Share by Supplier (2006)

2. Breast Disease Clinical Background and Statistics

2.1 Breast Anatomy
2.2 Malignant Breast Disease
2.2.1 Invasive Breast Cancer
2.2.2 Ductal Carcinoma in‐situ
2.2.3 Atypical Ductal Hyperplasia / Atypical Lobular Hyperplasia
2.2.4 Tumor Staging
2.3 Risk Factors: Breast Cancer
2.4 Disease Prevalence and Forecasts
2.5 Benign Breast Disease
2.5.1 Fibroadenoma
2.5.2 Cyst
2.5.3 Fibrocystic Disease
2.5.4 Benign Papilloma
2.6 Summary and Conclusions

Exhibit 2.1: Breast Anatomy and Malignant Disease States
Exhibit 2.2: Inconsistency in DCIS / ADH Diagnosis
Exhibit 2.3: Breast Cancer Staging and Survivability
Exhibit 2.4: Breast Cancer Staging and Treatment Options
Exhibit 2.5: US Population Trends
Exhibit 2.6: Breast Cancer Diagnosis and Mortality: Historical Trends and Forecasts
Exhibit 2.7: Breast Cancer Staging and Survivability
Exhibit 2.8: Worldwide Distribution of Breast Cancer
Exhibit 2.9: Benign Fibroadenoma Diagnoses Forecasts (2006-2012E)

3. Non‐Interventional Breast Disease Diagnosis

3.1 Screening and Diagnostic Mammography
3.1.1 Mammography Process
3.1.1.1 Acquisition
3.1.1.2 Review
3.1.1.3 Diagnostic Exam
3.1.1.4 Dedicated Mammography Center
3.1.2 Reimbursement
3.1.3 Product Offerings
3.1.3.1 Image Acquisition Systems
3.1.3.1.1 Direct Capture vs. Indirect Capture
3.1.3.1.2 Resolution
3.1.3.1.3 Cost
3.1.3.2 Market Analysis (Including Drivers, Limiters, and Opportunities)
3.1.4 Digital Mammography Workstations
3.1.4.1 Market Analysis (Including Drivers, Limiters, and Opportunities)
3.1.5 Digitizers
3.2 Computer Aided Diagnostics
3.2.1 Background
3.2.2 Market Analysis (Including Drivers, Limiters, and Opportunities)
3.3 Diagnostic Ultrasound
3.3.1 Ultrasound Technology
3.3.2 Diagnostic Ultrasound Procedure
3.3.3 Market Analysis (Including Drivers, Limiters, and Opportunities)
3.3.3.1 Non‐Breast Dedicated Radiology
3.3.3.2 Breast Dedicated Radiology
3.3.3.3 Surgeons
3.4 Screening Ultrasound
3.4.1 Technologies
3.4.1.1 Ultrasound computed tomography (CT)
3.4.1.2 Robotic Scanning
3.4.1.3 Ciné Approach
3.4.2 Market Analysis (Including Drivers, Limiters, and Opportunities)
3.5 Magnetic Resonance Imaging (MRI)
3.5.1 Technology Overview
3.5.2 Market Analysis (Including Drivers, Limiters, and Opportunities)
3.6 Other Diagnostic Methods:
3.6.1 Angiogenesis Monitors
3.7 PACS
3.8 S Summary and Conclusions
3.8.1 Screening and Diagnostic Mammography
3.8.2 Screening and Diagnostic Ultrasound
3.8.3 Magnetic Resonance Imaging
3.8.4 Other Non‐Interventional Modalities

Exhibit 3.1: Mammography
Exhibit 3.2: Mammographic Resolution
Exhibit 3.3: 2007 Medicare Reimbursement, Mammography
Exhibit 3.4: Economic Efficiency of Mammography Program, Effect of Personnel Efficiency
Exhibit 3.5: Economic Efficiency of Mammography Program, Effect of Digital versus Analog Technologies
Exhibit 3.6: Screening Mammogram Procedure Volumes, Historical (1991-2005)
Exhibit 3.7: Screening Mammogram Procedure Volume Forecast (2006-2012E)
Exhibit 3.8: Screening and Diagnostic Flowchart and Procedure Statistics
Exhibit 3.9: Reduction in Tumor Size at Diagnosis: Response to Screening Mammography Program
Exhibit 3.10: Changes in Cancer Staging at Diagnosis: Response to Screening Mammography Program
Exhibit 3.11: Distribution and Analysis of Mammography Centers in US
Exhibit 3.12: Full‐Field versus Analog Mammography System: Installed Base (2003-2012E)
Exhibit 3.13: Full‐Field Digital Mammography Systems: Detector Types
Exhibit 3.14: Full‐Field Digital vs. Analog Mammography Systems: Image Quality
Exhibit 3.15: Full‐Field Digital Mammography System Market Forecast (2006-2012E)
Exhibit 3.16: Full‐Field Digital Mammography System Market, Units, by Supplier (2006)
Exhibit 3.16: Full‐Field Digital Mammography System Market, Share by Supplier (2006)
Exhibit 3.19: Digital Mammography Workstations or Breast‐Specific PACS Sales Forecast (2006-2012E)
Exhibit 3.20: Digital Mammography Workstations Market, Share by Supplier (2006)
Exhibit 3.21: Breast Computer Aided Detection Market Analysis and Forecast: Successful Implementation of a Pay‐Per‐View Model
Exhibit 3.22: Breast Computer Aided Detection Market, Share by Supplier (2006)
Exhibit 3.23: Breast Ultrasound Images
Exhibit 3.24: Breast Ultrasound Market Analysis: Installed Units and Procedure Volumes
Exhibit 3.25: Breast Ultrasound Market: System Sales Forecast (2006-2012E)
Exhibit 3.26: Effectiveness of Various Diagnostic Techniques
Exhibit 3.27: Breast Ultrasound Market, Share as a Percentage of Total Medical Ultrasound Market (2006)
Exhibit 3.28: Breast Ultrasound Market, Share by Supplier( 2006)
Exhibit 3.29: Screening Breast Ultrasound Technologies
Exhibit 3.30: Screening Breast Ultrasound Market Forecast: Patient‐Pay, Rapid Adoption Scenario
Exhibit 3.31: Breast Mammography versus Breast MRI
Exhibit 3.32: Breast MRI: Number of Centers and Device Utilization (2007, 2012E)
Exhibit 3.33: Breast MRI Market Forecast, Units (2006-2012E)
Exhibit 3.34: Breast MRI Market Forecast, Revenue (2006-2012E)
Exhibit 3.35: Breast MRI Market, Share by Supplier (2006)
Exhibit 3.36: Non‐Interventional Breast Diagnostic System Sales Forecast (2006-2012E)
Exhibit 3.37: Non‐Interventional Breast Diagnostic System and Service Sales (2006-2012E)
Exhibit 3.38: Non‐Interventional Breast Diagnostic System and Service Sales, Share by Supplier (2006)

4. Interventional Breast Disease Diagnosis

4.1 Histopathology
4.2 Breast Specific Antigens
4.3 Ductal Lavage
4.4 Biopsy Methods
4.4.1 Guidance Methods
4.4.2 Fine Needle Aspiration
4.4.3 Spring‐Loaded Core Needle Biopsy:
4.4.4 Vacuum‐Assisted Core Needle Biopsy
4.4.5 Large‐Volume Contiguous Biopsy Devices
4.4.6 Biopsy Marking Devices
4.5 Reimbursement Considerations
4.6 Procedure Forecasts
4.6.1 Surgical Excision
4.6.2 Fine Needle Aspiration
4.6.3 Spring‐Loaded Core Needle Devices:
4.6.4 Vacuum‐Assisted Core Needle Devices
4.6.5 Large Volume / Intact Specimen Devices
4.6.6 Biopsy Marker Clips
4.7 Market Analysis (Including Drivers, Limiters, and Opportunities)
4.7.1 Surgical Excision
4.7.2 Fine Needle Aspiration
4.7.3 Spring‐Loaded Core Needle Biopsies
4.7.4 Vacuum‐Assisted Devices
4.7.5 Large Volume / Intact Specimen Devices
4.7.6 Marker Clips
4.8 Summary and Conclusions

Exhibit 4.1: Core Needle Biopsy Devices
Exhibit 4.2: Large‐Volume Contiguous Biopsy Devices
Exhibit 4.3: Diagnostic Accuracy of Stereotactic Biopsy Procedures
Exhibit 4.4: Relative Volumes of Biopsy Device Specimens
Exhibit 4.5: Medicare Reimbursement: Vacuum‐Assisted Biopsy Methods
Exhibit 4.6: Medicare Reimbursement: Spring‐Loaded Biopsy Methods
Exhibit 4.7: Stereotactic-Guided Biopsy: Vacuum Assisted Device: Example of Facility Profit
Exhibit 4.8: Excisional Biopsy Procedure Volume Forecast (2006-2012E)
Exhibit 4.9: Breast Biopsy Procedures, Historical (1990, 1994, 1998, 2002)
Exhibit 4.10: Breast Biopsy Procedure Volume Forecast (2006-2012E)
Exhibit 4.11: Breast Biopsy Market Procedure Volume Forecast (2006-2012E)
Exhibit 4.12: Spring‐Loaded Biopsy Device Market Forecast (2006-2012E)
Exhibit 4.13: Spring‐Loaded Biopsy Device Market, Share by Supplier (2006)
Exhibit 4.14: Vacuum‐Assisted Biopsy Device Market Forecast, Disposables vs. Capital Equipment (2006-2012E)
Exhibit 4.15: Vacuum‐Assisted Biopsy Device Market Forecast (2006-2012E)
Exhibit 4.16: Vacuum‐Assisted Biopsy Device Market, Share by Supplier (2006)
Exhibit 4.17: Biopsy Marker Device Market Forecast (2006-2012E)
Exhibit 4.18: Biopsy Marker Device Market, Share by Supplier (2006)

5. Breast Disease Therapies and Therapeutic Devices

5.1 Excision
5.1.1 Lumpectomy
5.1.2 Mastectomy
5.1.3 Lymphadectomies
5.1.3.1 Sentinel Lymph Node Excision
5.2 Radiation Therapy
5.2.1 Breast Brachytherapy
5.3 Ablation Therapies
5.4 Market Analysis (Including Drivers, Limiters, and Opportunities)
5.4.1 Excisional Devices
5.4.2 Brachytherapy Devices
5.4.3 Ablation Devices
5.5 Summary and Conclusions

Exhibit 5.1: Therapeutic Methods: Breast Conservation Therapy
Exhibit 5.2: Therapeutic Methods: Mastectomy
Exhibit 5.3: Excision Procedure Volume Forecast (2006-2012E)
Exhibit 5.4: Mastectomy Procedures: Inpatient vs. Outpatient
Exhibit 5.5: Lumpectomy Procedure Volume Forecast (2006-2012E)
Exhibit 5.6: Lumpectomy Procedure Volumes, by Tumor size (2006-2012E)
Exhibit 5.7: Breast Brachytherapy Illustration
Exhibit 5.8: Breast Brachytherapy Market Forecast (2006-2012E)
Exhibit 5.9: Tumor Cryoablation Illustration

6. Company Profiles

6.1 Aurora Imaging
6.2 CR Bard
6.3 Cytyc
6.4 FujiFilm
6.5 General Electric
6.6 Hologic
6.7 Johnson & Johnson (Ethicon Endo-Surgery)
6.8 Philips
6.9 SenoRx
6.10 Siemens
6.11 Suros Surgical
6.12 Toshiba

To order or inquire call 714 847 3540 or email at HYPERLINK sales@lifescienceintelligence.com




お申し込み先:
日本総代理店
株式会社テクトラン
電話:0551-20-5530
FAX: 0551-20-5531
e-mail: info@techtran.co.jp
代表取締役社長:牧野宝留